摘要
Kras基因在结直肠癌的发生、进展中起着重要的作用，同时也成为结直肠癌治疗重要的靶点。本文就Kras基因与结直肠癌的生物学特性、治疗以及Kras基因突变的检测作一综述。
出处
《浙江临床医学》
2009年第11期1233-1235,共3页
Zhejiang Clinical Medical Journal
参考文献27
-
1Frattini M, Saletti P, Romagnani E, et al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Brit J Cancer,2007,97(8) :1139 - 1145.
-
2Lea IA, Jackson MA, Li X, et al. Genetic pathways and mutation profiles of human cancers: site - and exposure - specific patterns. Carcinogenesis ,2007,28 (9) : 1851 - 1858.
-
3Andreyev H J, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: The ‘RASCAL Ⅱ' study. Br J Cancer,2001,85 ( 5 ) :692 - 696.
-
4Velho S, Moutinho C, Cirnes L,et al. BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis? BMC Cancer,2008,9 (8) :255.
-
5Samowitz WS, Curtin K, Sehaffer D, et al. Relationship of Ki - ras Mutations in Colon Cancers to Tumor Location, Stage, and Survival: A Population -based Study. Cancer Epidemiol Biomarkers Prey,2000,9 (11) :1193 - 1197.
-
6Calistri D, Rengucci C, Seymour I, et al. Mutation Analysis of p53, K- ras, and BRAF Genes in Colorectal Cancer Progression. J Cell Physio1,2005,204 (2) :484 - 488.
-
7Andreyev HJN, Norman AR, Cunningham D, et al. Kirsten Ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J Natl Cancer Inst, 1998,90 (9) :675-684.
-
8Conlin A, Smith G, Carey FA,et al. The prognostic significance of K -ras, p53, and APC mutations in colorectal carcinoma. Gut,2005, 54(9) :1283 - 1286.
-
9Petrowsky H, Stunn I, Graubitz O, et al. Relevance of Ki - 67 antigen expression and K - ras mutation in colorectal liver metastases. Eur J Surg Oncol,2001,27 ( 1 ) : 80 - 87.
-
10Bernhard E J, Stanbridge E J, Gupta S, et al. Direct evidence for the contribution of activated N - ras and K - ras oncogenes to increased intrinsic radiation resistance in human tumor cell lines. Cancer Res, 2000,60 ( 23 ) :6597 - 600.
同被引文献36
-
1沈琳.转移性结直肠癌靶向治疗个体化选择[J].肿瘤研究与临床,2008,20(8):507-508. 被引量：3
-
2Zhi-ZhongPan De-SenWan GongChert Li-RenLi Zhen-HaiLu Bi-JunHuang.Co-mutation of p53,K-rasgenes and accumulation of p53 protein and its correlation to clinicopathological features in rectal cancer[J].World Journal of Gastroenterology,2004,10(24):3688-3690. 被引量：4
-
3ZhiZhu,JingLin,Jian-HuiQu,MarkA.Feitelson,Can-RongNi,Fang-MeiLi,Ming-HuaZhu.Inhibitory effect of tumor suppressor p33^(ING1b) and its synergy with p53 gene in hepatocellular carcinoma[J].World Journal of Gastroenterology,2005,11(13):1903-1909. 被引量：10
-
4朱德斌,邢达,李贤,张岚.实时荧光等位基因特异性扩增法快速检测K-ras癌基因点突变[J].高等学校化学学报,2007,28(6):1031-1034. 被引量：3
-
5李陈婕,羊志辉,陈森林,周世权,莫晔,施小六.HER-2与K-RAS在结直肠癌中的表达及意义[J].解放军医学杂志,2007,32(6):598-600. 被引量：7
-
6Bishayee S. Role of conformational alteration in the epidermal growth factor receptor (EGFR) func-tion [ J ]. Biochem Pharmacol, 2000, 60 (8) : 1 217-1 223.
-
7Vairaktaris E, Loukeri S, Vassilious, et al. EGFR and e -jun exhibit the same patten of expres- sion and increase gradually during the progress of oral oneogenesis[J]. Clin Cancer Res,2007,21 (5) :791-6.
-
8Press M F, Sauter G, Bernstein L, et al. Di- agnostic evaluation of HER -2 as a molecular target: an assessment of accuracy and reproducibility of labo- ratory testing in large, prospective, randomized clini- cal trials [ J]. Clin Cancer Res, 2005, 11 (18):6 598-6 607.
-
9Margarit S M, Sondemann H, Hall B E, et al. Structural evidence for feedback activation by Ras GTP of the RAS specific muleotide exchange factor SOS[J]. Ce11,2003,112(5) :685 -695.
-
10Milusdomi T, Stinberg S M, Nau N H. p53 gene mutation in non small cell lung cancer line and their correlation with the presence of ras mutation and clinical feature [ J ]. Oncogene, 1992,7:171.
引证文献4
-
1王丽,余英豪.结直肠癌k-ras基因检测及其靶向治疗的研究现状[J].世界华人消化杂志,2011,19(1):62-67. 被引量：19
-
2王志强,赵文江,路新,陈国伟,李明洁,牛延军,姜秋,周喜元,曾高云,杨斌,李勇.K-ras与p33ING1、CyclinE在直肠癌组织中表达及生物学关系的研究[J].中华临床医师杂志（电子版）,2012,6(12):35-38.
-
3刘淼,王丹,李伟,索冰,程松.EGFR、HER2、c-jun、c-fos、P^(21)、P^(16)、P^(53)在非小细胞肺癌中的表达及临床病理特征[J].黑龙江医学,2012,36(9):643-645. 被引量：1
-
4盛霞,秦建民.分子病理学在结直肠癌诊断与个体化治疗和预后判断中的应用[J].中国现代医药杂志,2020,22(7):93-96. 被引量：1
二级引证文献21
-
1张雪,于淼,韩晶,胡旭华,刘嘉寅,李丹,刘妍,冯莉,王贵英.DUOX2在结肠腺癌中的表达及其对SW620和HCT116细胞恶性行为的影响[J].中华临床医师杂志（电子版）,2021,15(11):897-903.
-
2王丽,余英豪.EGFR靶向药物在结直肠癌中的研究进展[J].世界华人消化杂志,2011,19(10):1057-1062. 被引量：2
-
3王丽,余英豪,刘伟,王烈,欧阳学农,熊喜生.EGFR在结直肠癌组织中的表达及其意义[J].世界华人消化杂志,2011,19(14):1483-1488. 被引量：6
-
4李智,赵玉洲,韩广森,任莹坤,顾焱晖.大肠癌患者K-ras基因突变情况及临床意义[J].中华实用诊断与治疗杂志,2011,25(9):850-852. 被引量：3
-
5杨子峰,王锡明,唐军,乔红艳,张梦龙.结直肠癌T分期评估中双源CT个体化低剂量扫描可行性测试探讨[J].医学影像学杂志,2012,22(6):941-945. 被引量：9
-
6陈丽芳,余英豪.结直肠癌潜在预后标志物的研究进展[J].世界华人消化杂志,2012,20(25):2377-2381. 被引量：4
-
7高颖,昌红,沈兵,石峰,张建英.应用ADx-ARMS法对大肠癌组织中K-ras基因突变的检测[J].中国医药导报,2013,10(14):101-103.
-
8高平,高亚杰.抑癌基因p16与胃腺癌患者XELOX方案化疗预后的关系[J].世界华人消化杂志,2013,21(26):2724-2727.
-
9高颖,昌红,沈兵,石峰,张建英.大肠癌组织中K-ras基因突变的检测[J].诊断病理学杂志,2013,20(10):634-637.
-
10贺红娟,陈尔飞,雷蕾.肿瘤发生与相关基因突变的关联[J].基因组学与应用生物学,2015,34(1):208-214. 被引量：14
-
1王俊茹,邓国仁,刘为纹.ras基因突变与人类肿瘤[J].癌症,1993,12(1):81-84. 被引量：12
-
2杨定成.RAS基因突变和人类肿瘤的发生[J].实用癌症杂志,1992,7(3):222-225. 被引量：1
-
3张钊,刘胜利.KRAS基因突变与结直肠癌研究进展[J].东南大学学报（医学版）,2016,35(1):154-157. 被引量：9
-
4丛晶,姜乃光,许红.P^(21)蛋白和PCNA在胃癌中的表达、相互关系及其意义[J].黑龙江医学,1998,0(3):7-7.
-
5王晓波,梅骅.前列腺癌中ras基因突变及p21蛋白表达研究[J].中华实验外科杂志,1997,14(6):380-380. 被引量：4
-
6要洁,冯奉仪.大肠癌的化疗现状与展望[J].中国肿瘤临床,2003,30(12):898-900. 被引量：2
-
7于志伟,董新舒,王锡山,李钰,付松滨.大肠癌原发性耐药与p53、ras基因突变的关系[J].中华肿瘤杂志,2002,24(5):480-480. 被引量：3
-
8荚敏,黄培林.KRAS基因在胰腺癌发生发展中的作用[J].东南大学学报（医学版）,2014,33(4):513-516. 被引量：3
-
9祁秀敏,张熔熔,孙屏.KRAS基因突变与大肠癌临床病理特征及预后的关系[J].江苏医药,2017,43(7):464-467. 被引量：4
-
10李艳菊,张春莉,尹香利,惠起源.结直肠癌KRAS基因突变检测及临床意义[J].延安大学学报（医学科学版）,2015,13(2):45-46.
